










































The investigative burden of Membranous Nephropathy in the
United Kingdom
Citation for published version:
Hamilton, P, Wilson, F, Chinnadurai, R, Sinha, S, Singh, M, Ponnusamy, A, Hall, P, Dhaygude, A,
Kanigicherla, D & Brenchley, P 2019, 'The investigative burden of Membranous Nephropathy in the United
Kingdom' Clinical kidney journal. DOI: 10.1093/ckj/sfz036
Digital Object Identifier (DOI):
10.1093/ckj/sfz036
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 09. May. 2019
O R I G I N A L A R T I C L E
The investigative burden of membranous
nephropathy in the United Kingdom
Patrick Hamilton 1,2, Fiona Wilson1, Rajkumar Chinnadurai 2,3,
Smeeta Sinha2,3, Malinder Singh4, Arvind Ponnusamy4, Peter Hall5,
Ajay Dhaygude4, Durga Kanigicherla1,2 and Paul Brenchley1,2
1Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK,
2Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, 3Vascular Research
Group, Salford Royal Hospital, Salford, UK, 4Royal Preston Hospital, Sharoe Green Lane North, Fulwood,
Preston, UK and 5Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine,
Western General Hospital, Edinburgh, UK
Correspondence and offprint requests to: Patrick Hamilton; E-mail: Patrick.hamilton@mft.nhs.uk
ABSTRACT
Background. Membranous nephropathy (MN) represents two distinct disease entities. Primary MN is now recognized as an
autoimmune condition associated with the anti-PLA2R antibody and secondary MN occurs in tandem with malignancy,
infection, drug therapy and other autoimmune conditions. Prior to the development of accessible enzyme-linked
immunosorbent assays, the diagnosis of MN was one of exclusion. We studied whether the introduction of serum anti-
PLA2R antibody testing leads to a reduction in the frequency of investigations in MN patients.
Methods. Patients from three UK centres with a diagnosis of MN between 2009 and 2014 were identified. We compared
patients who had a positive anti-PLA2R test within 6 months of biopsy with those who had no test or a negative test.
Records were reviewed for investigations that took place 6 months prior to and 6 months following the biopsy date to see if
these were normal or identified a secondary cause of MN.
Results. In total, 184 patients were included: 80 had no test, 66 had a negative anti-PLA2R test and 38 had a positive test
within 6 months of diagnosis. In 2012, 46.5% of patients had an anti-PLA2R test, increasing to 93.3% in 2014. From 2012 to
2014 the number of screening tests dropped from 10.03 to 4.29 and the costs from £497.92 to £132.94.
Conclusions. Since its introduction, a progressively higher proportion of patients diagnosed with MN had an anti-PLA2R
test. This has led to a reduction in the number of screening tests and in the cost of investigations carried out. The anti-
PLA2R test has the potential to reduce this burden as its use becomes more widespread.
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INTRODUCTION
Membranous nephropathy (MN) is among the most common
causes of nephrotic syndrome in adults worldwide [1–6]. For
decades it has been a histological diagnosis with two distinct
entities: primary or autoimmune membranous nephropathy
(PMN) and secondary MN. Despite their histological similarities,
the pathogenesis and treatments differ greatly, meaning that
differentiating between the two conditions is essential.
Secondary MN is associated with a multitude of conditions such
as malignancy, viral infections such as hepatitis B and C, medi-
cations and other autoimmune conditions such as lupus and
toxins [7–9]. As such, management is aimed at treating the un-
derlying condition.
PMN, originally known as idiopathic MN, has always been
considered an autoimmune disease, although the offending an-
tibody remained elusive until the discovery of antibodies to the
M-type phospholipase receptor 1 (anti-PLA2R) in 2009 [10–15].
This immunoglobulin G class antibody is found in 75% of
patients with PMN and has high affinity for podocytes [10, 16,
17]. There is now considerable evidence to suggest that not only
is it a sensitive biomarker of disease activity, but also patho-
genic in its own right. High titres are known to correlate with
disease activity, and for patients who go into remission, the
anti-PLA2R levels decrease months before clinical signs, such as
a reduction in proteinuria. The converse is also true with re-
lapse predated by an increase in antibody levels [13, 14, 18–21].
The antibody level can also help to provide some level of prog-
nostication, with high titres associated with a worse renal out-
come compared with low titres [13]. If treatment does not result
in antibody negativity, patients are left with a high risk of re-
lapse. In fact, if treatment does not result in antibody negativity,
then they are left with a high risk of relapse and a reduction in
anti-PLA2R level strongly predicts remission [18, 20, 22].
The benefit of regular anti-PLA2R testing led to the introduc-
tion of the first quantitative anti-PLA2R enzyme-linked immu-
nosorbent assay (ELISA) test, which was developed in
Manchester and became available across the northwest of
England towards the end of 2011 [13]. Since then a commercial
anti-PLA2R test has been developed and is now readily available
internationally [23]. Prior to the development of these ELISAs,
PMN was a diagnosis of exclusion. Given the association of sec-
ondary MN with malignancy and given the disease itself is gen-
erally a disease of middle age and older, many patients undergo
a number of invasive procedures in order to rule out neoplastic
disease. At present, there is no universally accepted consensus
on the investigative pathway for primary or secondary MN. In
patients with PMN, this results in many being procedures per-
formed, with normal findings, at a cost not only to the patient
in terms of quality of life, but also a societal cost to health care
systems with limited resources.
Hypothesis
With the anti-PLA2R test becoming more ubiquitous, the intro-
duction of anti-PLA2R antibody testing leads to a reduction in
the frequency of investigations for patients with MN.
MATERIALS ANDMETHODS
All adult patients with biopsy-proven MN between 2009 and
2014 from three large teaching hospitals in the northwest of
England covering a population of 7 million were included in
the study. Patients were excluded if biopsy was not conclusive
of MN. Patients were identified from patient records and histo-
pathology results from each centre.
Day 0 was taken as the date of renal biopsy. Records were
reviewed for investigations that took place 6 months prior to
and 6 months following the biopsy date to see if these were nor-
mal or identified a secondary cause of MN. Investigations in-
cluded viral and autoimmune screens, X-rays, computed
tomography (CT) scans, magnetic resonance imaging (MRI), pos-
itron emission tomography (PET) scans, ultrasound scans, up-
per and lower gastrointestinal (GI) endoscopies and
cystoscopies. Investigations were excluded if they were not per-
formed in relation to the diagnosis of primary versus secondary
MN.
Records were also interrogated to determine if a patient had
an anti-PLA2R test and at what date. The result was only in-
cluded if the sample was also taken within 6 months of the date
of biopsy. A positive anti-PLA2R test was taken as >40 U/mL for
the ELISA and a titre of >1:10 for the Euroimmun indirect immu-
nofluorescence test (IIFT). A negative ELISA was taken as <40 U/
mL and a titre of  1:10 for the Euroimmun IIFT [13].
Costs were assigned to each investigation in pounds sterling
and taken from the National Health Service (NHS) reference
costs for 2015–16 [24]. For chest and abdominal X-rays, the costs
were taken from the NHS England National Tariff for 2015–16
[25]. The cost of anti-PLA2R testing was not included (Table 1).
For each patient, a total cost was determined for the
investigations they underwent, using the resource costs as
Table 1. Cost of investigations
Investigation
Mean
value LQR UQR Source
Hepatitis B 6.42 4.02 7.65 DAPS06 NHS ref costs
Hepatitis C 6.42 4.02 7.65 DAPS06 NHS ref costs
HIV 6.42 4.02 7.65 DAPS06 NHS ref costs
RF 6.42 4.02 7.65 DAPS06 NHS ref costs
ds-DNA 6.42 4.02 7.65 DAPS06 NHS ref costs
ANA 6.42 4.02 7.65 DAPS06 NHS ref costs
Complement 6.42 4.02 7.65 DAPS06 NHS ref costs
PSA 1.18 0.78 1.39 DAPS04 NHS ref costs
ANCA 6.42 4.02 7.65 DAPS06 NHS ref costs
TFTs 1.18 0.78 1.39 DAPS04 NHS ref costs
Chest X-ray 25.00 National tariff
Abdominal X-ray 25.00 National tariff
CT head 93.93 65.19 115.59 RD20A NHS ref costs
CT thorax 102.50 70.75 134.97 RD21A NHS ref costs
CT abdomen 102.50 70.75 134.97 RD21A NHS ref costs
CT TAP 120.70 88.30 138.91 RD26Z NHS ref costs
MRI 145.14 113.26 173.53 RD01A NHS ref costs
PET 798.20 430.64 1213.54 RN07A NHS ref costs
OGD 352.21 322.20 432.22 FZ60Z NHS ref costs
Colonoscopy 371.27 236.45 521.90 FZ51Z NHS ref costs
Sigmoidoscopy 207.69 152.04 247.24 FZ54Z NHS ref costs
USS abdomen 50.62 38.54 60.44 RD40Z NHS ref costs
Cystoscopy 151.71 101.68 175.50 LB72A NHS ref costs
All costs in British pound sterling. NHS ref costs, National Health Service refer-
ence costs 2015–16 [18]; National tariff, National Health Service non-mandatory
currencies and prices 2015–16 [19]; LQR, lower quartile range; UQR, upper quar-
tile range; HIV, human immunodeficiency virus; RF, rheumatoid factor; dsDNA,
double-stranded deoxyribonucleic acid; ANA, anti-nuclear antibody; ANCA,
antineutrophil cytoplasmic antibody; PSA, prostate-specific antigen; CT, com-
puted tomography; MRI, magnetic resonance imaging; PET, positron emission
tomography; OGD, oesophagogastroduodenoscopy; USS, ultrasound scan; TFTs,
thyroid function tests; TAP, thorax, abdomen and pelvis.
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Table 2. Demographics
Parameter No anti-PLA2R Negative anti-PLA2R Positive anti-PLA2R Total
Patients 80 (43) 66 (36) 38 (21) 184 (100)
Age at diagnosis (years), mean (SD) 59 (15.58) 57 (15.64) 57 (13.19) 58 (15.10)
Gender
Female 32 (40) 24 (36) 11 (29) 67 (36)
Male 48 (60) 42 (64) 27 (71) 117 (64)
Hepatitis B
Negative test 38 (48) 28 (42) 13 (34) 79 (43)
No test 42 (52) 38 (58) 25 (66) 105 (57)
Hepatitis C
Negative test 38 (48) 28 (42) 12 (32) 78 (42)
No test 42 (52) 38 (58) 26 (68) 106 (58)
HIV
Negative test 17 (21) 20 (30) 12 (32) 49 (27)
No test 63 (79) 46 (70) 26 (68) 135 (73)
Rheumatoid factor
Negative test 31 (39) 17 (26) 8 (21) 56 (30)
No test 48 (60) 48 (73) 30 (79) 126 (68)
Positive test 1 (1) 1 (2) 0 (0) 2 (1)
Anti-dsDNA
Negative test 44 (55) 44 (67) 26 (68) 114 (62)
No test 35 (44) 22 (33) 12 (32) 69 (38)
Positive test 1 (1) 0 (0) 0 (0) 1 (1)
ANA
Negative test 61 (76) 53 (80) 29 (76) 143 (78)
No test 18 (22) 12 (18) 9 (24) 39 (21)
Positive test 1 (1) 1 (2) 0 (0) 2 (1)
Complement (C3/C4)
Negative test 60 (75) 48 (73) 27 (71) 135 (73)
No test 19 (24) 17 (26) 11 (29) 47 (26)
Positive test 1 (1) 1 (2) 0 (0) 2 (1)
PSA
Negative test 11 (14) 13 (20) 10 (26) 34 (18)
No test 68 (85) 53 (80) 28 (74) 149 (81)
Positive test 1 (1) 0 (0) 0 (0) 1 (1)
ANCA
Negative test 61 (76) 50 (76) 31 (82) 142 (77)
No test 19 (24) 16 (24) 7 (18) 42 (23)
TFTs
Negative test 30 (38) 18 (27) 20 (53) 68 (37)
No test 50 (62) 48 (73) 18 (47) 116 (63)
CXR
Positive test 3 (4) 1 (2) 0 (0) 4 (2)
Negative test 39 (49) 33 (50) 21 (55) 93 (51)
No test 38 (48) 32 (48) 17 (45) 87 (47)
AXR
Negative test 4 (5) 1 (2) 1 (3) 6 (3)
No test 76 (95) 65 (98) 37 (97) 178 (97)
CT head
Negative test 3 (4) 2 (3) 3 (8) 8 (4)
No test 77 (96) 64 (97) 35 (92) 176 (96)
CT thorax
Positive test 0 (0) 1 (2) 0 (0) 1 (1)
Negative test 6 (8) 1 (2) 5 (13) 12 (7)
No test 74 (92) 64 (97) 33 (87) 171 (93)
CT abdomen
Positive test 0 (0) 1 (2) 0 (0) 1 (1)
Negative test 2 (2) 1 (2) 1 (3) 4 (2)
No test 78 (98) 64 (97) 37 (97) 179 (97)
CT TAP
Positive test 2 (2) 1 (2) 0 (0) 3 (2)
Negative test 20 (25) 15 (23) 9 (24) 44 (24)
No test 58 (72) 50 (76) 29 (76) 137 (74)
(continued)






/ckj/advance-article-abstract/doi/10.1093/ckj/sfz036/5476564 by Edinburgh U
niversity user on 25 April 2019
mentioned above. The mean cost and number of investiga-
tions with 95% confidence intervals (CIs) were calculated
with standard bootstrapping using 10 000 samples with re-
placement [26, 27].
The number of investigations and the cost of investigations
per year were then analysed based on the presence of a positive
anti-PLA2R versus a negative test or no sample taken.
Significance was calculated using the Student’s t-test and
Table 2. Continued
Parameter No anti-PLA2R Negative anti-PLA2R Positive anti-PLA2R Total
MRI
Negative test 1 (1) 1 (2) 1 (3) 3 (2)
No test 79 (99) 65 (98) 37 (97) 181 (98)
PET
Positive test 0 (0) 1 (2) 0 (0) 1 (1)
No test 80 (100) 65 (98) 38 (100) 183 (99)
OGD
Positive test 0 (0) 1 (2) 0 (0) 1 (1)
Negative test 11 (14) 8 (12) 4 (11) 23 (12)
No test 69 (86) 57 (86) 34 (89) 160 (87)
Colonoscopy
Positive test 1 (1) 0 (0) 0 (0) 1 (1)
Negative test 7 (9) 8 (12) 5 (13) 20 (11)
No test 72 (90) 58 (88) 33 (87) 163 (89)
Sigmoidoscopy
Negative test 0 (0) 0 (0) 1 (3) 1 (1)
No test 80 (100) 66 (100) 37 (97) 183 (99)
USS abdomen
Negative test 41 (51) 33 (50) 20 (53 94 (51)
No test 39 (49) 33 (50) 18 (47) 90 (49)
Cystoscopy
Negative test 0 (0) 1 (2) 3 (8) 4 (2)
No test 80 (100) 65 (98) 35 (92) 180 (98)
All values are presented as n (%) unless stated otherwise.
HIV, human immunodeficiency virus; ANA, anti-nuclear antibody; PSA, prostate-specific antigen; ANCA, anti-neutrophil cytoplasmic antibodies; TFTs, thyroid func-
tion tests; CXR, chest X-ray; AXR, abdominal X-ray; CT, computed tomography scan; TAP, thorax, abdomen and pelvis; MRI, magnetic resonance imaging; PET, positron
emission tomography; OGD, oesophagogastroduodenoscopy; USS, ultrasound scan.
FIGURE 1: Proportion of MN patients with anti-PLA2R testing.
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FIGURE 2: Proportion of each investigation with no anti-PLA2R testing, a negative anti-PLA2R test and a positive anti-PLA2R test, based on whether the investigation
was positive or negative. C3/C4, complement C3/C4; RF, rheumatoid factor; Hep, hepatitis.
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defined as <0.05. All analyses were carried out using R statisti-
cal software version 3.4.3 (R Foundation for Statistical
Computing, Vienna, Austria) [28].
RESULTS
A total of 184 patients across the three hospitals were included.
The mean age of our cohort at diagnosis was 58 years, with a
predominance of male patients (64%). A total of 80 (43%)
patients did not undergo anti-PLA2R testing within 6 months of
the date of biopsy and 104 (57%) patients did have an anti-PLA2R
test within 6 months of the date of biopsy; 66 (63% of those
tested) had a negative test and 38 (37% of those tested) had a
positive test (Table 2 and Figure 2). Of the 184 patients included
in the study, 21 (11.4%) were confirmed as secondary MN. Of
these 21 patients, 9 were tested for anti-PLA2R and all were
negative.
Frequency of anti-PLA2R testing
In 2011, when the anti-PLA2R test became available locally, it
was only used in 8 of 20 (40%) patients diagnosed with MN.
Since that time there has been a steady increase in the number
of patients tested for anti-PLA2R within 6 months of their bi-
opsy, with 93.3% of patients having the test in 2014 (Table 3 and
Figure 1).
Number of investigations
There were a total of 1230 investigations performed in all
patients, of which only 20 were positive and led to a diagnosis
of secondary MN. From 2011 onwards, there is a reduction in
the number of investigations performed in anti-PLA2R seroposi-
tive patients. In 2012, the first full year of anti-PLA2R availabil-
ity, there was a mean of 6.85 tests (95% CI 5.61–8.09) per patient
in those with no anti-PLA2R testing or a negative test. In the se-
ropositive group, the mean number of tests was 6.59 (95% CI
4.9–8.2). This difference was not statistically significant
(P¼0.823). In 2014, the mean number of tests performed per pa-
tient in the seropositive group decreased to 4.29 tests (95% CI
2.6–6.1) compared with 9.01 in seronegative patients; this repre-
sented a significant difference (95% CI 6.6–11.02; P ¼ 0.019;
Table 4).
Cost of investigations
The total cost of investigations within 6 months of biopsy for all
patients was £39 177.83 and, of this, £5533.04 was spent on
investigations with a result leading to a diagnosis of secondary
MN. In patients with no anti-PLA2R testing or a negative result,
the cost of investigations remained relatively stable over the
years at £220.27 (95% CI 137.93–315.77) in 2009 and £244.11 (95%
CI 109.88–429.97) in 2014. In patients with a positive anti-PLA2R,
the cost of investigations decreased each year from its introduc-
tion, going from £497.92 (95% CI 89.83–909.00) in 2011 to £132.94
(95% CI 29.66–309.44) in 2014, although the difference in cost per
year was not significant between the groups (Table 4).
DISCUSSION
The majority of patients with a histological diagnosis of MN will
have primary MN, an autoimmune disease in which 70–80% are
anti-PLA2R positive [10]. Since its discovery in 2009, our under-
standing of the condition has vastly improved, with evidence
suggesting the pathogenic nature of the antibody [13, 19–21].
This, coupled with its relative absence in secondary MN [29],
makes it a valuable biomarker not only for disease activity, but
also for diagnosis.
Prior to the development of the anti-PLA2R blood test, the di-
agnosis of PMN was one of exclusion at a cost to patients and
the health care system. In our cohort, the vast majority of









2009 39 39 (100.0) 0 (0.0)
2010 28 28 (100.0 0 (0.0)
2011 20 12 (60.0) 8 (40.0)
2012 43 23 (53.5) 20 (46.5)
2013 39 15 (38.5) 24 (61.5)
2014 15 1 (6.7) 14 (93.3)
Number of patients who did and did not have an anti-PLA2R test within
6 months of the date of biopsy.
Table 4. Number of tests and cost of tests based on year of biopsy and anti-PLA2R test status
Year of diagnosis No test or anti-PLA2R negative Anti-PLA2R positive P-value
Cost of tests (£)
2009 220.27 (137.93–315.77) NA (NA) NA
2010 216.93 (120.46–328.56) NA (NA) NA
2011 227.07 (85.92–392.93) 497.92 (89.83–909.00) 0.363
2012 161.16 (106.45–227.11) 226.39 (111.68–369.71) 0.414
2013 225.64 (107.82–395.67) 218.88 (107.62–383.89) 0.946
2014 244.11 (109.88–429.97) 132.94 (29.66–309.44) 0.405
Number of investigations
2009 6.87 (5.90–7.82) NA (NA) NA
2010 6.89 (5.57–8.18) NA (NA) NA
2011 4.57 (2.75–6.62) 10.03 (5.00–14.5) 0.164
2012 6.85 (5.61–8.09) 6.59 (4.90–8.20) 0.823
2013 6.44 (5.04–7.88) 8.08 (6.21–9.71) 0.177
2014 9.01 (6.60–11.2) 4.29 (2.60–6.10) 0.019
Values presented as mean (95% CI). NA, not available.
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investigations carried out for this reason were negative, a use of
resources that is considerable given MN is one of the most com-
mon causes of adult nephrotic syndrome worldwide [1–6].
Here we show that use of the test has increased over the
years, with a higher proportion of our patients with a tissue di-
agnosis of MN undergoing concomitant anti-PLA2R testing; 93%
of patients in 2014 compared with only 46.5% in 2012. Along
with increased use of anti-PLA2R testing, there is a correspond-
ing reduction in the number of other investigations being car-
ried out and a reduction in the cost of investigations.
Approximately one-third of patients with a diagnosis of PMN
will go into spontaneous remission, most within the first year
[30]. For this reason, and along with the complications associ-
ated with immunosuppression, patients have traditionally been
treated with supportive care through inhibition of the renin–
angiotensin–aldosterone system for 6 months before consider-
ing immunosuppression [7]. However, in the anti-PLA2R era,
more proactive management may be warranted. It has now
been shown that seronegative patients or those with low anti-
PLA2R are more likely to go into spontaneous remission and less
likely to suffer from renal decline [13, 31]. Conversely, patients
with high anti-PLA2R at diagnosis are more likely to have dis-
ease progression, worsening renal function and higher levels of
proteinuria [13, 21, 31]. The reduction of anti-PLA2R and subse-
quent reduction in proteinuria has been shown in a number of
studies to improve outcomes following treatment [19–21]. It has
also long been shown that achieving either partial or complete
remission leads to better long-term outcomes [32, 33].
There is still some debate, however, around the benefits of
early immunosuppression. In a randomly controlled trial, early
immunosuppression did appear to lead to remission quicker
than postponing immunosuppressive therapy, with a similar
adverse event profile. At the end of the 6-year follow-up, 86% of
patients in the early immunosuppression group had achieved
remission compared with 67% in the late treatment group.
However, there was no statistical difference in serum creati-
nine, albumin or proteinuria [34]. Given the relatively short
follow-up time with respect to the long disease course of MN,
over time one could speculate that a difference may have been
observed. This study was also carried out in the pre-anti-PLA2R
era when disease severity was based on proteinuria. By utilizing
the anti-PLA2R titre, those patients with high levels who are un-
likely to go into spontaneous remission and have a higher
chance of disease progression could have a shorter time to
treatment without the need to wait for unnecessary invasive
investigations.
As use of the anti-PLA2R test becomes more widespread and
physician confidence in its ability to differentiate primary from
secondary MN and to prognosticate disease progression
increases, it has the potential to radically change management
practice. As seen in our study, patients traditionally undergo a
large number of invasive investigations in order to rule out pa-
thology, and the majority of these understandably come back
with nothing abnormal detected. Not only is the cost to the
patients’ quality of life a consideration, but also the cost to the
health care system, with the use of resources that could be
diverted elsewhere. This is especially true given that the cost of
the anti-PLA2R test, currently offered in the UK by the Protein
Reference Unit in Sheffield, is £25.81 per sample. This makes it
cheaper than many of the investigations patients are currently
subjected to.
Our study does have a number of limitations, in particular
the likely underestimate of investigations carried out. In the
Greater Manchester and Preston region, renal medicine
operates in a hub-and-spoke manner, with specialist renal
departments centralized in large teaching hospitals and
patients transferred or referred in from smaller satellite units
around the region. This means that some investigations may
well have been carried out in the satellite unit before the
patients’ transfer of care, and although the majority of these
investigations would be expected to be low-cost tests, such as
biochemistry, there may be a number of scans and endoscopies
that may not have been accounted for. As this was a retrospec-
tive analysis based on patient records, another limitation is the
unknown societal cost of anti-PLA2R testing, for example, the
cost of transport or missed workdays. As there is a general trend
towards a reduction in the frequency of investigations in those
patients undergoing anti-PLA2R testing, one could expect to see
a reduction in the associated costs to society. However, this
would need to be confirmed in a prospective trial. As with any
retrospective study, there are inherent limitations involved; a
randomly controlled trial to investigate the effect of anti-PLA2R
testing on the investigative pathway would be ideal. However,
given its proven sensitivity and specificity for MN, it would now
be unethical to consider the care of a patient with anti-PLA2R-
positive MN without the use of the antibody level.
The number of positive anti-PLA2R tests in our cohort was
lower than reported in other studies, with most reporting in the
region of 70–80% of MN patients [10, 14, 19]. There were, how-
ever, a large number of patients in the earlier years of its use
that were not tested. As the test became more ubiquitous over
time, the percentage of positive samples better reflected the lit-
erature. For example, in 2014 there were 14 anti-PLA2R tests, of
which 10 were positive, representing 71% of patients.
The use of anti-PLA2R is not infallible, with a number of case
reports identifying patients with secondary MN and elevated
anti-PLA2R [35–38]. Whether this is coincidental, given that
patients in the age group most affected by MN are also at risk of
malignancy, is yet to be proven conclusively. Each patient still
needs a careful and thorough history and examination and in-
vestigation as appropriate.
Saying this, as the anti-PLA2R test becomes commonplace in
patients with nephrotic syndrome, its use can help to reduce
the burden of investigations for both the patient and society
and its use should be included in future management guide-
lines and research.
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